Business Wire
- Business Wire
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
– New examination of AURORA 1 Phase 3 data demonstrates increased renal response rates with LUPKYNIS™ (voclosporin) used in combination with MMF and low-dose steroids in patients with lupus nephritis regardless of target urine protein…
Read More »